Author

Yun-Jiang Liu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).

B. Lan, Ye-Hui Shi, Xi-Ying Shao et al. · The Lancet · 0 citations

Review Open access Oct 2026

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.

Importance Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer. Objective To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...

Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al. · Journal of the American Medi... · 1 citation

Review Open access Oct 2026

Glycemic biomarkers and cardiovascular disease in diabetes: a comparative analysis of population-based and clinical cohorts

Background Cardiovascular disease (CVD) remains a major complication contributing to morbidity and mortality among individuals with diabetes. Different glycemic biomarkers reflect distinct aspects of glucose metabolism, but their associations with prevalent CVD across different diabetic populations remain incompletely...

Li-Hong Zhang, Meng-Zhen Liu, Yu Zhang et al. · Frontiers in Endocrinology · 0 citations